Effect of lamivudine against HBV reinfection after liver transplantation
Shi-Chun Lu,Lu-Nan Yan,Bo Li,Tian-Fu Wen,Ji-Chun Zhao,Nan-Sheng Cheng,Chong Liu,Jun Liu,Xiao-Bo Wang,Xiao-Dong Li,Shan Qin,Lian-Shan Zhao,Bin-Jun Lei,Xiu-Hui Zhang
DOI: https://doi.org/10.11569/wcjd.v11.i2.185
2003-01-01
World Chinese Journal of Digestology
Abstract:AIM: To assess the prophylactic effect of lamivudine in preventing reinfection of HBV and the dynamic alternations of HBV markers in serum and liver tissue after liver transplantation. METHODS: Twenty five recipients were non-randomly divided into HBV active replicating group (15 cases) and HBV non-active replicating group (10 cases) and control group (3 cases). Lamivudine 100 mg/day was administered to each patient before and after operation, 3 of 10 cases in non-active replicating group failed to take lamivudine on time and thus was grouped as control. The HBV markers in serum and bioptic liver tissues in 25 recipients were evaluated regularly with enzyme-linked radioimmunoassay, HBV DNA fluorescent quantitative assay, immunohistochemistry stain LSAB and digoxin labeled HBV DNA hybridization in situ. replication became negative following 2-week periods of lamivudine treatment prior to liver transplantation. HBsAg in all recipients converted to negative after liver transplantation. HBsAb (9/15), HbcAb(13/15) and HBeAb (11/15) appeared within one week postoperatively, and disappeared gradually within 6 months. Serum HBV DNA was negative; Results of in situ hybridization in bioptic liver tissue showed that HBsAg, HBcAg as well as HBV DNA remained negative after treatment of lamivudine. 10 of 15 recipients had got to clinical clearance of HBV, HBV markers were undetectable in both serum and liver biopsy samples between 12 to 44 weeks (average 24 weeks), 1-, 2-year survival rate in this group reached 83%. Two of 15 subjects (13.3 %) developed allograft HBV reinfection or recurrence of hepatitis in 2 years after the prophylactic treatment of lamivudine. In HBV non-active replicating group, the outcome was similar with that in the active group. The HBV antibody was HBsAb (+, 4/7), HBcAb (+, 6/7), HBeAb (+, 2/7), 3 of 7 recipients achieved HBV clinical clearance in both serum and liver bioptic samples, while in control group, all 3 redpients developed allograft HBV reinfection and recurrent hepatitis in 8, 10 and 12 months post- transplantation, respectively, one of three died from fibrosing cholestatic hepatitis, the other 2 cases recovered after the additional therapy of lamivudine. The overall allograft reinfection rate was 9.1% (2/22) and the overall 1-, 2-year accumulative survival rate was 87% in patients received lamivudine. CONCLUSION: Lamivudine can effectively prevent liver allograft from HBV reinfection in HBV related decompensated liver cirrhosis and even in HBV active replicating recipient.